Ketryx, the agentic continuous compliance platform for safety-critical product development, announced that William A. Hawkins, former Chairman and CEO of Medtronic, has joined its Board of Directors. Hawkins also participated in the company’s Series B financing, signaling strong industry support for Ketryx's mission to solve the AI bottleneck in life sciences.
Hawkins, who led Medtronic from 2007 to 2011, brings decades of experience in medical device innovation and regulatory strategy. His appointment comes as Ketryx expands its platform to help companies in safety-critical industries—including medical devices, pharmaceuticals, and robotics—accelerate product development by automatically generating compliant documentation, maintaining continuous traceability, and enabling safe and verifiable AI at scale.
“The life sciences industry is at a critical inflection point where AI can dramatically improve patient outcomes, but only if companies can navigate the complex regulatory landscape,” said Hawkins. “Ketryx’s platform addresses this challenge head-on by embedding compliance into the development process, allowing teams to innovate faster without sacrificing safety or quality.”
Ketryx’s platform overlays existing tools to automate documentation, create traceability, and accelerate release cycles without disrupting workflows. Its AI agents reduce manual work by up to 90 percent, helping teams identify and close compliance gaps. This approach is trusted by four of the world’s top five medical device manufacturers.
The news highlights the growing importance of AI in regulated industries, where traditional development processes often slow innovation. By automating compliance, Ketryx enables companies to focus on product development while ensuring adherence to strict regulatory standards. For more information, visit www.ketryx.com.
